National Pharmaceutical Pricing Authority (NPPA) has reportedly imposed a penalty of around Rs 300 crore on Novartis for over pricing its popular painkilling medicine Voveran. The company has also received a show cause notice to explain in two weeks why action should not be taken against it for overcharging.
Novartis India is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare.